Compounding pharmacies have become central to the peptide and weight loss medication conversation. They're the reason tirzepatide can cost $150/month instead of $1,100. But misinformation about them runs in both directions — some people think they're dangerous, others think they're identical to brand-name manufacturers. The truth is in the middle.
What Compounding Actually Is
Compounding is the practice of creating customized medications for individual patients. A doctor writes a prescription. A pharmacist prepares the medication to that specific prescription. This has been standard pharmacy practice for over a century — long before mass-manufactured drugs existed.
Modern compounding handles situations that mass manufacturing doesn't:
- A patient is allergic to an inactive ingredient in the brand-name version
- A medication is needed in a different dose, concentration, or form (liquid vs tablet, different strength)
- A brand-name drug is on shortage or prohibitively expensive
- A medication needs to be combined with other compounds in a single preparation
503A vs 503B: The Two Types
503A pharmacies are traditional compounding pharmacies. They fill individual prescriptions for specific patients. Think of your local pharmacy, but with the ability to customize medications. They're regulated primarily by state boards of pharmacy.
503B pharmacies (also called outsourcing facilities) are a newer category created by the Drug Quality and Security Act of 2013. They can produce larger batches without individual prescriptions, essentially functioning as small-scale manufacturers. They're subject to more rigorous FDA oversight, including current Good Manufacturing Practices (cGMP) and regular FDA inspections.
Most telehealth weight loss platforms partner with 503B facilities because they can produce medications at scale, maintain more consistent quality control, and meet higher regulatory standards.
How Quality Control Works
A well-run compounding pharmacy operates under strict protocols:
Ingredient sourcing
APIs (active pharmaceutical ingredients) must come from FDA-registered suppliers. The tirzepatide API used in compounding is chemically identical to what Eli Lilly uses — it's pharmaceutical-grade material from regulated sources.
Testing
Finished compounds should undergo potency testing (confirming the right amount of active ingredient), sterility testing (for injectable products), endotoxin testing, and beyond-use dating verification. 503B facilities are required to perform these tests. 503A pharmacies should, but enforcement varies by state.
Certificates of Analysis (COA)
Legitimate pharmacies can provide a COA for any product they compound. This document shows test results for potency, purity, and sterility. If a pharmacy can't or won't provide a COA, that's a major red flag.
Sterile compounding
Injectable medications require sterile compounding in clean rooms with specific air quality standards, gowning procedures, and environmental monitoring. This is the area where quality variance between pharmacies is most significant and most important.
Why Compounded Drugs Cost Less
The price difference isn't about quality — it's about business model. Brand-name drug prices include:
- ●Billions in R&D costs (Eli Lilly spent $2B+ developing tirzepatide)
- ●FDA clinical trial costs ($100M-500M per drug)
- ●Marketing and sales force costs
- ●Patent-protected profit margins
- ●Shareholder returns
Compounding pharmacies skip all of this. They use the same pharmaceutical-grade active ingredient but don't carry R&D, marketing, or patent costs. A compounding pharmacy's costs are: ingredient sourcing, labor, quality testing, and overhead. That's why the same compound can cost $150/month compounded versus $1,100 brand-name.
The active ingredient isn't cheaper because it's lower quality. It's cheaper because the pharmacy's cost structure is fundamentally different.
Legitimate Concerns
Compounding isn't without real risks:
Variability
Brand-name manufacturers have extremely tight tolerances on potency (typically +/- 5%). Compounding pharmacies can have wider variance depending on their quality practices. A good 503B facility matches manufacturer tolerances. A poor-quality pharmacy might not.
Sterility failures
The most serious risk with compounded injectables. The 2012 NECC fungal meningitis outbreak — which killed 76 people — happened at a compounding facility with egregious quality control failures. This event led directly to the 503B regulatory framework. Modern 503B facilities operating under cGMP are vastly safer, but the risk isn't zero.
Regulatory gaps
503A pharmacies face less federal oversight than 503B facilities. Quality varies significantly. Some states have strong pharmacy board oversight; others don't.
How to Verify a Pharmacy
Check state licensure
Every compounding pharmacy must be licensed in the state(s) where it operates. You can verify this through the state board of pharmacy website.
Check 503B registration
If the pharmacy claims 503B status, verify it on the FDA's outsourcing facility list (publicly available on the FDA website).
Ask for the COA
Request a certificate of analysis for the specific product. A legitimate pharmacy will provide this readily.
Check for FDA warning letters
The FDA publishes warning letters to compounding pharmacies on its website. Search before using a pharmacy.
Look for accreditation
PCAB (Pharmacy Compounding Accreditation Board) accreditation is voluntary but indicates a higher standard of quality. Not all good pharmacies have it, but having it is a positive signal.
The bottom line: compounding pharmacies aren't inherently risky, and they aren't all the same. The 503B facilities partnering with major telehealth platforms are generally held to high standards. But you should still verify — your health is worth the 10 minutes it takes to check a pharmacy's credentials.